TY  - GEN
AU  - Scott,Frank I
AU  - Luo,Michelle
AU  - Shah,Yash
AU  - Lasch,Karen
AU  - Vajravelu,Ravy K
AU  - Mamtani,Ronac
AU  - Fennimore,Blair
AU  - Gerich,Mark E
AU  - Lewis,James D
TI  - Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis
SN  - 1876-4479
PY  - 2021///0414
KW  - Adalimumab
KW  - therapeutic use
KW  - Adult
KW  - Algorithms
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Azathioprine
KW  - Biological Products
KW  - economics
KW  - Colectomy
KW  - Colitis, Ulcerative
KW  - drug therapy
KW  - Cost-Benefit Analysis
KW  - statistics & numerical data
KW  - Drug Therapy, Combination
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Infliximab
KW  - Male
KW  - Markov Chains
KW  - Models, Economic
KW  - Quality-Adjusted Life Years
KW  - Tumor Necrosis Factor-alpha
KW  - antagonists & inhibitors
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1093/ecco-jcc/jjz212
ER  -